SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009887
Filing Date
2023-05-15
Accepted
2023-05-15 16:31:34
Documents
47
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20230331x10q.htm   iXBRL 10-Q 1273327
2 EX-31.1 apre-20230331xex31d1.htm EX-31.1 9714
3 EX-31.2 apre-20230331xex31d2.htm EX-31.2 10535
4 EX-32.1 apre-20230331xex32d1.htm EX-32.1 6697
5 EX-32.2 apre-20230331xex32d2.htm EX-32.2 6711
  Complete submission text file 0001558370-23-009887.txt   3612023

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20230331.xsd EX-101.SCH 24599
7 EX-101.CAL apre-20230331_cal.xml EX-101.CAL 26511
8 EX-101.DEF apre-20230331_def.xml EX-101.DEF 104551
9 EX-101.LAB apre-20230331_lab.xml EX-101.LAB 220400
10 EX-101.PRE apre-20230331_pre.xml EX-101.PRE 167322
41 EXTRACTED XBRL INSTANCE DOCUMENT apre-20230331x10q_htm.xml XML 304700
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 23923194
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences